August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 15, 2025

Autoimmune Diseases Tied to Different Digestive Cancer Risks

Researchers examined celiac disease, SLE, MS, and T1D in relation to cancers of the pancreas, stomach, esophagus, small intestine, colon, rectum, liver, and gallbladder.

Conexiant

July 11, 2025

Patients With Sludge Pancreatitis Have Fewer Complications

An international cohort study found that patients with sludge- or microlithiasis-induced acute pancreatitis had significantly fewer long-term complications than those with gallstone-related pancreatitis.

Conexiant

July 26, 2023

Volume of Liver Resected During Gallbladder Surgery May Not Significantly Affect Overall Survival in Patients With Gallbladder Cancer

Investigators have found that overall survival rates may not vary significantly among patients with gallbladder cancer who have had different volumes of their livers resected, as long as the cancer is...

The ASCO Post

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

March 14, 2025

Incretin Drugs Linked to Gallbladder Disease Risk

Prescribers should be aware of the risk of gallbladder and biliary tract diseases when using incretin-based drugs in patients with T2D regardless of BMI status, study shows.

Conexiant

December 03, 2024

FDA Greenlights Yesintek Biosimilar

Conexiant